Skip to Main Content

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT)

Conditions

Diseases of the Musculoskeletal System

Phase III

What is the purpose of this trial?

Brief Summary:

To evaluate the safety and tolerability of FG-3019 in subjects with IPF, and the efficacy of FG-3019 in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these subjects.

  • Trial with
    Ra Pharmaceuticals, Inc.
  • Start Date
    06/30/2020
  • End Date
    12/30/2020
Trial Image

For more information about this study, contact:

Joan Nye

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/09/2020
  • Study HIC
    #2000026786